Gregory Scott Welmaker

This inventor holds 26 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent, primarily in Leukocyte Adhesion Inhibition. Top assignees: Wyeth, Elan Pharmaceuticals, Inc., American Home Products Corporation. Active years: 2002-2011.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gregory Scott Welmaker. Retrieved from https://idiyas.com/inventor/gregory-scott-welmaker

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26

% Patents Active = 19.2

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 1

Average Co-Inventor Count = 5.7

ph-index = 8

Forward Citations = 140(Granted Patents)

Location History:

Collegeville, PA (US) (2006 - 2010)
Jackson, NJ (US) (2002 - 2011)

Company Filing History:

Elan Pharmaceuticals, Inc.

patents

1 out of 1,567

American Home Products Corporation

patents

4. 5 out of 834,453

Other

patents

where one patent can have more than one assignee

Years Active: 2002-2011

Loading Chart...

Areas of Expertise:

Leukocyte Adhesion

Integrin Inhibitors

Potassium Channel Modulators

Alpha Amino Acid Derivatives

Beta Amino Acid Derivatives

Heteroaryl Compounds

Cyclopenta Diazepino

Tetracyclic Indoles

Phenylalanine Derivatives

Heterocyclic Compounds

Aryl Compounds

Pyrazinoquinoxalin Derivatives

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7973044 - Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 (2011-07-05),

2. 7968547 - Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 (2011-06-28),

3. 7745454 - Alpha amino acid derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 (2010-06-29),

4. 7662831 - Tetracyclic indoles as potassium channel modulators (2010-02-16),

5. 7601856 - Benzofurans as potassium ion channel modulators (2009-10-13),

6. 7378529 - Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 (2008-05-27),

7. 7351839 - Process for the preparation of 1,2,3,4,8,9,10, 10a-octahydro-7bH-cyclopenta[b][1,4]diazepino-[6,7,1-hi]indole derivatives (2008-04-01),

8. 7291645 - Phenylalanine derivatives as alpha 4 integrin inhibitors (2007-11-06),

9. 7271163 - Cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives (2007-09-18),

10. 7223762 - Beta-amino acid derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 (2007-05-29),

11. 7141563 - Process for the preparation of 1, 2, 3, 4, 8, 9, 10, 10a-octahydro-7bH-cyclopenta[b] [1, 4]diazepino[6, 7, 1-hi] indole derivatives (2006-11-28),

12. 7098338 - 2,3,4,4a-tetrahydro-1H-pyrazino(1,2-a) quinoxalin-5(6H)one derivatives (2006-08-29),

13. 7015216 - Heteroaryl-β-alanine derivatives as alpha 4 integrin inhibitors (2006-03-21),

14. 6953802 - Beta-amino acid derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 (2005-10-11),

15. 6911439 - Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 (2005-06-28),

Title: Gregory Scott Welmaker: Innovator in Pharmaceutical Compounds

Introduction

Gregory Scott Welmaker is an accomplished inventor based in Jackson, NJ, known for his significant contributions to the field of pharmaceutical innovations. With a remarkable portfolio of 26 patents, Welmaker has dedicated his career to developing compounds that have the potential to treat various inflammatory diseases.

Latest Patents

Among his latest patents is a groundbreaking invention titled "Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4." This patent discloses compounds that effectively bind to VLA-4, thereby inhibiting leukocyte adhesion, which is crucial in the treatment of numerous inflammatory diseases. The implications of these compounds are extensive, as they may be useful in addressing conditions such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis, and myocardial ischemia. Additionally, these compounds can be administered to treat inflammatory brain diseases, including multiple sclerosis.

Career Highlights

Throughout his career, Gregory Scott Welmaker has worked with prominent companies in the pharmaceutical industry, including Wyeth and Elan Pharmaceuticals, Inc. His expertise and innovative approach have allowed him to make significant strides in the development of therapeutic solutions for patients suffering from inflammatory conditions.

Collaborations

Welmaker has collaborated with esteemed individuals in the industry, including Andrei William Konradi and Eugene D. Thorsett. These partnerships have enriched his research and facilitated the advancement of his innovative compounds, leading to more effective treatments.

Conclusion

Gregory Scott Welmaker’s contributions to pharmaceutical innovations highlight his commitment to improving patient outcomes through science. His extensive patent portfolio and collaborations with leading pharmaceutical companies affirm his role as a pivotal figure in the field of invention. As research continues to evolve, Welmaker remains at the forefront, dedicated to advancing technologies that have the potential to transform healthcare.

Profile summary based on public USPTO records.